Injectable HIV Therapy Held Viral Suppression Across Eastern and Southern Africa
For adults living with HIV in eastern and southern Africa, adherence remains one of the most stubborn barriers to durable viral control. Oral therapy works when pills are taken consistently, but real-world treatment success often breaks down long before pharmacology does. In this phase 3b trial, a long-acting injectable regimen of cabotegravir plus rilpivirine performed as well as daily oral dolutegravir-based therapy in people who already had viral suppression but struggled with adherence or ongoing care engagement.
The study enrolled 540 participants across seven sites in Kenya, South Africa, and Uganda, with 537 included in the primary analysis. Participants were randomly assigned in equal numbers to receive intramuscular cabotegravir 600 mg plus rilpivirine 900 mg every 8 weeks, after the first two injection visits were spaced 4 weeks apart, or to continue daily oral dolutegravir-based therapy. Viral suppression at baseline was already in place, defined as a viral load below 200 copies per milliliter, which matters because the clinical question here was not initial treatment response but maintenance under very different delivery models.
Noninferiority Was Met at Week 48
At week 48, 244 of 268 participants in the long-acting group, or 91.0%, had a viral load below 50 copies per milliliter. In the oral-therapy group, 240 of 269 participants, or 89.2%, reached the same endpoint. The risk difference was 1.9 percentage points, with a 95% confidence interval from -3.1 to 6.9, meeting the prespecified noninferiority margin of -10 percentage points. A per-protocol analysis aligned with the main result, reinforcing the robustness of the primary finding.
The endpoint is clinically meaningful because it measures sustained suppression at a threshold associated with durable treatment success and reduced risk of transmission. In practical terms, the injectable strategy did not need to outperform oral therapy; it only needed to preserve suppression without falling meaningfully behind. It did so despite a population selected for adherence challenges, a setting in which pill-based regimens can be vulnerable to missed doses, treatment fatigue, and disrupted clinic engagement.
Virologic Failure Was Uncommon but Clustered in the Injectable Arm
Confirmed virologic failure occurred in 5 participants in the long-acting group, or 1.9%, and in no participants in the oral group. The risk difference was 1.9 percentage points, with a 95% confidence interval from 0.3 to 3.5. This finding does not erase the noninferiority result, but it does create a clinically important counterweight: a long-acting regimen reduces dependence on daily pill-taking, yet it also introduces a different failure mode if drug exposure is delayed, interrupted, or pharmacologically mismatched to a patient’s resistance profile.
Baseline drug-resistance testing was not performed, which leaves a gap in interpretation. Long-acting cabotegravir-rilpivirine depends on maintaining sufficient drug levels over time, and archived resistance could compromise one component of the dual regimen without warning. The injectable approach can stabilize adherence behavior, but it cannot fully neutralize virologic risk rooted in preexisting resistance or missed injection timing.
Safety Profile Stayed Broadly Comparable
Serious adverse events were reported in 11 of 271 participants receiving long-acting therapy, or 4.1%, and in 8 of 269 participants receiving oral therapy, or 3.0%. The risk difference was 1.1 percentage points, with a 95% confidence interval from -1.1 to 4.2. No major safety divergence emerged from the abstracted data, which is important because a regimen designed to improve retention and suppression cannot do so at the cost of unacceptable toxicity.
The injectable platform carries a different adherence biology than pills. Once administered, the medication bypasses day-to-day patient action, converting adherence from a repeated behavioral task into a clinic-based schedule. For people whose viral suppression is undermined by missed tablets, unstable housing, stigma, travel, or competing life demands, that shift can be decisive. The price is loss of immediate reversibility; once a long-acting injection is given, the drug remains in the body for weeks, so any interruption in follow-up becomes more consequential than with a short-acting oral regimen.
What This Means for HIV Care Delivery
This trial speaks directly to one of the central problems in contemporary HIV care: treatment failure is often not a failure of efficacy, but a failure of sustained medication access and adherence. In a region where approximately 1 million people living with HIV and receiving oral therapy do not have viral suppression because of adherence challenges, a regimen that preserves suppression without requiring daily pill-taking has real operational value. The result does not suggest that injectable therapy should replace oral treatment for everyone. It does suggest that long-acting therapy can be used as a targeted strategy for selected adults with suppression but unreliable engagement on oral therapy.
The enrolled population already had HIV type 1 suppression below 200 copies per milliliter, so this was a maintenance study, not an induction study. That distinction matters at the bedside. Clinicians considering long-acting therapy still need to assess the likelihood of returning for injections, the feasibility of every-8-week visits after the initial loading schedule, and the potential consequences if a patient disappears from care. The dual-drug injectable model may lower the cognitive and behavioral burden of daily treatment, but it shifts part of the burden onto the health system, which must keep patients connected to the injection schedule.
The Remaining Clinical Friction Points
The study was conducted at seven sites in Kenya, South Africa, and Uganda, and the findings therefore reflect care delivery in specific African clinical settings rather than a universally generalizable program. The absence of baseline resistance testing leaves uncertainty about which patients are best suited to the injectable regimen and which may be at higher risk for failure. The 48-week follow-up also answers only the early durability question. Longer observation will matter because long-acting therapy creates a new pharmacologic tail, and long-term implementation will depend on whether clinics can sustain reliable injection delivery without interruptions.
Even with those limitations, the core message is direct: cabotegravir plus rilpivirine maintained viral suppression as effectively as oral dolutegravir-based therapy in adults with adherence challenges across multiple African sites. The trial shows that a long-acting regimen can substitute for daily pills without sacrificing short-term virologic control, while also reminding clinicians that injectable treatment introduces its own adherence and resistance considerations, just in a different form.